Abstract
Aberrant activation of the PI3K/Akt/mTOR pathway is found in many types of cancer and thus plays a major role in breast cancer cell proliferation and anti-cancer drug resistance. The mechanisms involved in the activation of this pathway include: constitutively activated receptor tyrosine kinases (IGF/IGFR, ErbB, FGF/FGFR systems) leading to constitutive activation of PI3K; loss of PTEN function; PI3K mutations; aberrant activation of Akt, eIF4E, 4E-BP1 and p70S6K. These alterations trigger a cascade of biological events, from cell growth and proliferation to survival and migration, which contribute to tumor progression. Therefore, the PI3K/Akt/mTOR pathway is considered an attractive target for the development of novel anti-cancer molecules, and several specific tyrosine kinase inhibitors and signal transduction inhibitors specifically targeting the kinases involved in this pathway have been developed. Many of these inhibitors currently under clinical evaluation represent a promising approach for the treatment of breast cancer patients. This review provides an overview of the most recent patents, of pre-clinical and clinical studies of inhibitors targeting the different members and/or activators of the PI3K/Akt/mTOR pathway, used alone or in combination with other targeted agents for the treatment of breast cancer.
Keywords: Breast cancer, PI3K/Akt/mTOR pathway, PI3K inhibitors, Akt inhibitors, mTOR inhibitors, tyrosine kinase inhibitors, combination therapies, pre-clinical studies, clinical trials, patents
Recent Patents on Anti-Cancer Drug Discovery
Title: Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer Patients
Volume: 5 Issue: 1
Author(s): Sandra E. Ghayad and Pascale A. Cohen
Affiliation:
Keywords: Breast cancer, PI3K/Akt/mTOR pathway, PI3K inhibitors, Akt inhibitors, mTOR inhibitors, tyrosine kinase inhibitors, combination therapies, pre-clinical studies, clinical trials, patents
Abstract: Aberrant activation of the PI3K/Akt/mTOR pathway is found in many types of cancer and thus plays a major role in breast cancer cell proliferation and anti-cancer drug resistance. The mechanisms involved in the activation of this pathway include: constitutively activated receptor tyrosine kinases (IGF/IGFR, ErbB, FGF/FGFR systems) leading to constitutive activation of PI3K; loss of PTEN function; PI3K mutations; aberrant activation of Akt, eIF4E, 4E-BP1 and p70S6K. These alterations trigger a cascade of biological events, from cell growth and proliferation to survival and migration, which contribute to tumor progression. Therefore, the PI3K/Akt/mTOR pathway is considered an attractive target for the development of novel anti-cancer molecules, and several specific tyrosine kinase inhibitors and signal transduction inhibitors specifically targeting the kinases involved in this pathway have been developed. Many of these inhibitors currently under clinical evaluation represent a promising approach for the treatment of breast cancer patients. This review provides an overview of the most recent patents, of pre-clinical and clinical studies of inhibitors targeting the different members and/or activators of the PI3K/Akt/mTOR pathway, used alone or in combination with other targeted agents for the treatment of breast cancer.
Export Options
About this article
Cite this article as:
Ghayad E. Sandra and Cohen A. Pascale, Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer Patients, Recent Patents on Anti-Cancer Drug Discovery 2010; 5 (1) . https://dx.doi.org/10.2174/157489210789702208
DOI https://dx.doi.org/10.2174/157489210789702208 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HIF Prolyl 4-Hydroxylases and their Potential as Drug Targets
Current Pharmaceutical Design Identification of Molecular Targets Associated with Ethanol Toxicity and Implications in Drug Development
Current Pharmaceutical Design An Update on the Other Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Medicinal Chemistry Reviews - Online (Discontinued) Design, Synthesis and Antitumor Activity of Dimeric Bile Acid-Amino Acid Conjugates
Letters in Organic Chemistry Cellular Therapy for Ovarian Cancer: Experimental and Clinical Perspectives
Current Medicinal Chemistry Metal Complexes of Uracil Derivatives with Cytotoxicity and Superoxide Scavenging Activity
Letters in Drug Design & Discovery Design, Synthesis and Biological Evaluation of 1H-1,2,3-Triazole-Linked-1H-Dibenzo[b,h]xanthenes as Inductors of ROS-Mediated Apoptosis in the Breast Cancer Cell Line MCF-7
Medicinal Chemistry Development of a Mimotope-Based Vaccine Against CD20 Antigen
Protein & Peptide Letters A Facile Synthesis and Anticancer Activity Evaluation of Spiro Analogues of Benzothiazolylchromeno/pyrano Derivatives
Letters in Drug Design & Discovery Role of Nitric Oxide in Physiology and Pathology of the Gastrointestinal Tract
Mini-Reviews in Medicinal Chemistry Green Tea Polyphenols as Proteasome Inhibitors: Implication in Chemoprevention
Current Cancer Drug Targets Biotechnological Approaches for the Treatment of Inflammatory Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Novel Therapeutic Approaches to Regulate Human Dihydrofolate Reductase Activity and Expression
Current Enzyme Inhibition Microsatellite Instability (MSI) as Genomic Marker in Endometrial Cancer: Toward Scientific Evidences
Mini-Reviews in Medicinal Chemistry Beyond Bile Acids: Targeting Farnesoid X Receptor (FXR) with Natural and Synthetic Ligands
Current Topics in Medicinal Chemistry Integrating Qualitative and Quantitative Tools for the Detection and Identification of Lectins in Major Human Diseases
Protein & Peptide Letters Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology Synthesis, DNA Binding Ability and Anticancer Activity of 2-heteroaryl Substituted Benzimidazoles Linked Pyrrolo[2,1-c][1,4]benzodiazepine Conjugates
Medicinal Chemistry Sorafenib (BAY 43-9006): Review of Clinical Development
Current Clinical Pharmacology Can Radiology Replace Endoscopy in IBD?
Current Drug Targets